- $4.05bn
- $3.45bn
- $1.11bn
ISS backs election of Langer to replace former Biogen director Denner (updated)
Biogen conflicts cry out for boardroom therapy
Brief: Sarissa Issues Presentation On Need For Shareholder Representation On Alkermes Board
Sarissa's Denner quits Biogen board as firm seeks seats at Alkermes (updated)
Sarissa's Denner quits Biogen board as firm seeks seats at Alkermes
Brief: Alkermes PLC Issues Letter To Shareholders
Brief: Sarissa Capital Management Urges Alkermes Shareholders To Vote “For” Election Of Sarissa Nominees
Brief: Alkermes Publishes Investor Presentation Detailing Company's Transformation And Value Creation
Brief: Alkermes Announces Final Award In Janssen Pharmaceutica Arbitration
Brief: Alkermes Appoints Caroline Loew As Chief Executive Officer Designate Of Mural Oncology PLC
Brief: Alkermes Files Definitive Proxy Statement And Issues Letter To Shareholders Detailing Business Execution That Has Driven Strong Performance And Delivered Shareholder Value
Brief: Alkermes Files Preliminary Proxy Statement And Provides Update On Annual Director Nomination Process
Alkermes Plc reports results for the quarter ended in March - Earnings Summary
Brief: Alkermes Q1 net loss USD 41.8 million
Brief: Alkermes Q1 revenue USD 287.6 million
Brief: Alkermes PLC Reports First Quarter 2023 Financial Results
Alkermes Plc expected to post a loss of 2 cents a share - Earnings Preview
Brief: Alkermes Announces Application Period For 2023 Alkermes Inspiration Grants Program
Brief: Alkermes Announces Submission Of Confidential Draft Form 10 Registration Statement For Planned Separation Of Oncology Business